Sep 12, 2022 / 01:30PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Biotech Equity Research Analyst
Good morning, everyone. And thank you for joining H.C. Wainwright 24th Annual Global Investment Conference. My name is Arthur He, and I'm a biotech equity research analyst at H.C. Wainwright.
Please welcome, our next presenter, Dr. Manny Litchman, the CEO and the President of Mustang Bio. Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancers and genetic disease. Manny, the floor is yours.
Manny Litchman - Mustang Bio, Inc. - President, CEO & Director
Thanks very much, Arthur. And thanks, everybody, for your interest in Mustang Bio. So Mustang Bio was pioneering innovative CAR-T therapies for cancer, as well as gene therapies for primary immunodeficiencies.
Our key assets are our people. We have about 110 or so people on University of Massachusetts Medical School campus in that state-of-the-art manufacturing facility that you see at the right. And our lead programs, are MB-106, a first-in-class CD20
Mustang Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
